Clinical Trial Update: Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CAL-263 for allergic rhinitis completed; study assessed effects of CAL-263 in subjects exposed to allergen in an environmental chamber.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• CAL-263

Snippet

Sponsor: Gilead Sciences | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED